Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

ORACLE: observational ctDNA surveillance across early-stage solid tumors

Observational study of a ctDNA assay for recurrence detection after curative-intent treatment, with cohorts in bladder, lung, breast, melanoma, gastroesophageal, gastric, pancreatic, head and neck, ovarian, endometrial, kidney, and colorectal cancers. ClinicalTrials.gov lists the study as recruiting.

Guardant Health, Inc.